Protection against Vibrio vulnificus infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein

Vaccine

Volumn 32, Issue 2, 2014, Pages 271-276

  Lee, Tae Hee ^a   Kim, Mi Hyun ^a   Lee, Chang Seop ^a   Lee, Ju Hyung ^a   Rhee, Joon Haeng ^b   Chung, Kyung Min ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Passive immunization; RtxA1 MARTXVv; Therapy; Vaccine; Vibrio vulnificus

Indexed keywords

BACTERIAL PROTEIN; PROTEIN RTXA1 C; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL LOAD; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIBRIO VULNIFICUS INFECTION;

PASSIVE IMMUNIZATION; RTXA1/MARTX(VV); THERAPY; VACCINE; VIBRIO VULNIFICUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL LOAD; BACTERIAL TOXINS; BACTERIAL VACCINES; FEMALE; IMMUNE SERA; IMMUNIZATION, PASSIVE; MICE; RECOMBINANT PROTEINS; VIBRIO INFECTIONS;

EID: 84890562499     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.019     Document Type: Article

References (48)

1. Baffone W., Tarsi R., Pane L., Campana R., Repetto B., Mariottini G.L., et al. Detection of free-living and plankton-bound vibrios in coastal waters of the Adriatic Sea (Italy) and study of their pathogenicity-associated properties. Environmental Microbiology 2006, 8:1299-1305.
2. Myatt D.C., Davis G.H. Isolation of medically significant Vibrio species from riverine sources in south east Queensland. Microbios 1989, 60:111-123.
3. Oliver J.D., Warner R.A., Cleland D.R. Distribution and ecology of Vibrio vulnificus and other lactose-fermenting marine vibrios in coastal waters of the southeastern United States. Applied and Environmental Microbiology 1982, 44:1404-1414.
4. Bisharat N., Agmon V., Finkelstein R., Raz R., Ben-Dror G., Lerner L., et al. Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group. Lancet 1999, 354:1421-1424.
5. Blake P.A., Merson M.H., Weaver R.E., Hollis D.G., Heublein P.C. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. The New England journal of Medicine 1979, 300:1-5.
6. Feldhusen F. The role of seafood in bacterial foodborne diseases. Microbes and Infection 2000, 2:1651-1660.
7. Linkous D.A., Oliver J.D. Pathogenesis of Vibrio vulnificus. FEMS Microbiology Letters 1999, 174:207-214.
8. Strom M.S., Paranjpye R.N. Epidemiology and pathogenesis of Vibrio vulnificus. Microbes and Infection 2000, 2:177-188.
9. Jones M.K., Oliver J.D. Vibrio vulnificus: disease and pathogenesis. Infection and Immunity 2009, 77:1723-1733.
10. Gulig P.A., Bourdage K.L., Starks A.M. Molecular pathogenesis of Vibrio vulnificus. Journal of Microbiology 2005, 43:118-131.
11. Satchell K.J. Structure and function of MARTX toxins and other large repetitive RTX proteins. Annual Review of Microbiology 2011, 65:71-90.
12. Jeong H.G., Satchell K.J. Additive function of Vibrio vulnificus MARTX(Vv) and VvhA cytolysins promotes rapid growth and epithelial tissue necrosis during intestinal infection. PLoS Pathogens 2012, 8:e1002581.
13. Kim Y.R., Lee S.E., Kook H., Yeom J.A., Na H.S., Kim S.Y., et al. Vibrio vulnificus RTX toxin kills host cells only after contact of the bacteria with host cells. Cellular Microbiology 2008, 10:848-862.
14. Lee B.C., Choi S.H., Kim T.S. Vibrio vulnificus RTX toxin plays an important role in the apoptotic death of human intestinal epithelial cells exposed to Vibrio vulnificus. Microbes and Infection 2008, 10:1504-1513.
15. Lee J.H., Kim M.W., Kim B.S., Kim S.M., Lee B.C., Kim T.S., et al. Identification and characterization of the Vibrio vulnificus rtxA essential for cytotoxicity in vitro and virulence in mice. Journal of Microbiology 2007, 45:146-152.
16. Chung K.J., Cho E.J., Kim M.K., Kim Y.R., Kim S.H., Yang H.Y., et al. RtxA1-induced expression of the small GTPase Rac2 plays a key role in the pathogenicity of Vibrio vulnificus. The Journal of Infectious Diseases 2010, 201:97-105.
17. Lo H.R., Lin J.H., Chen Y.H., Chen C.L., Shao C.P., Lai Y.C., et al. RTX toxin enhances the survival of Vibrio vulnificus during infection by protecting the organism from phagocytosis. The Journal of Infectious Diseases 2011, 203:1866-1874.
18. Lee T.H., Kim Y.R., Rhee J.H., Kim J.H., Woo H.R., Chung K.M. Characterization of monoclonal antibodies targeting the RtxA1 toxin of Vibrio vulnificus. Process Biochemistry 2011, 46:1500-1508.
19. Di Paolo D., Lenci I., Cerocchi C., Tariciotti L., Monaco A., Brega A., et al. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transplant International: Official Journal of the European Society for Organ Transplantation 2010, 23:1105-1112.
20. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18:1217-1225.
21. Mitchell M.S., Kan-Mitchell J., Kempf R.A., Harel W., Shau H.Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Research 1988, 48:5883-5893.
22. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunology and Cell Biology 2004, 82:488-496.
23. Rickman L.S., Gordon D.M., Wistar R., Krzych U., Gross M., Hollingdale M.R., et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 1991, 337:998-1001.
24. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. The New England Journal of Medicine 2002, 347:1652-1661.
25. Chung K.M., Diamond M.S. Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice. Journal of Medical Virology 2008, 80:547-556.
26. Karem K.L., Poon A.C., Bierl C., Nisenbaum R., Unger E. Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay. Clinical and Diagnostic Laboratory Immunology 2002, 9:577-582.
27. Amend D.F. Potency testing of fish vaccines. Developments in Biological Standardization 1981, 49:447-454.
28. Kim Y.R., Lee S.E., Kang I.C., Nam K.I., Choy H.E., Rhee J.H. A bacterial RTX toxin causes programmed necrotic cell death through calcium-mediated mitochondrial dysfunction. The Journal of Infectious Diseases 2013, 207:1406-1415.
29. Horseman M.A., Surani S. A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases 2011, 15:e157-e166.
30. Kreger A.S., Gray L.D., Testa J. Protection of mice against Vibrio vulnificus disease by vaccination with surface antigen preparations and anti-surface antigen antisera. Infection and Immunity 1984, 45:537-543.
31. Wright A.C., Powell J.L., Kaper J.B., Morris J.G. Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus. Infection and Immunity 2001, 69:6893-6901.
32. Wright A.C., Powell J.L., Tanner M.K., Ensor L.A., Karpas A.B., Morris J.G., et al. Differential expression of Vibrio vulnificus capsular polysaccharide. Infection and Immunity 1999, 67:2250-2257.
33. Yoshida S., Ogawa M., Mizuguchi Y. Relation of capsular materials and colony opacity to virulence of Vibrio vulnificus. Infection and Immunity 1985, 47:446-451.
34. Devi S.J., Hayat U., Frasch C.E., Kreger A.S., Morris J.G. Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model. Infection and Immunity 1995, 63:2906-2911.
35. Hayat U., Reddy G.P., Bush C.A., Johnson J.A., Wright A.C., Morris J.G. Capsular types of Vibrio vulnificus: an analysis of strains from clinical and environmental sources. The Journal of Infectious Diseases 1993, 168:758-762.
36. Devi S.J., Hayat U., Powell J.L., Morris J.G. Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus. Infection and Immunity 1996, 64:2220-2224.
37. Chen Y.C., Chang C.C., Chang S.Y., Su J.H. A recombinant metalloprotease antigen of Vibrio vulnificus elicits protective antibodies in a murine model. Letters in Applied Microbiology 2010, 50:168-172.
38. Fan J.J., Shao C.P., Ho Y.C., Yu C.K., Hor L.I. Isolation and characterization of a Vibrio vulnificus mutant deficient in both extracellular metalloprotease and cytolysin. Infection and Immunity 2001, 69:5943-5948.
39. Jeong H.S., Jeong K.C., Choi H.K., Park K.J., Lee K.H., Rhee J.H., et al. Differential expression of Vibrio vulnificus elastase gene in a growth phase-dependent manner by two different types of promoters. The Journal of Biological Chemistry 2001, 276:13875-13880.
40. Shao C.P., Hor L.I. Metalloprotease is not essential for Vibrio vulnificus virulence in mice. Infection and Immunity 2000, 68:3569-3573.
41. Chang A.K., Kim H.Y., Park J.E., Acharya P., Park I.S., Yoon S.M., et al. Vibrio vulnificus secretes a broad-specificity metalloprotease capable of interfering with blood homeostasis through prothrombin activation and fibrinolysis. Journal of Bacteriology 2005, 187:6909-6916.
42. Kothary M.H., Kreger A.S. Purification and characterization of an elastolytic protease of Vibrio vulnificus. Journal of General Microbiology 1987, 133:1783-1791.
43. Miyoshi S., Shinoda S. Role of the protease in the permeability enhancement by Vibrio vulnificus. Microbiology and Immunology 1988, 32:1025-1032.
44. Kwak J.S., Jeong H.G., Satchell K.J. Vibrio vulnificus rtxA1 gene recombination generates toxin variants with altered potency during intestinal infection. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:1645-1650.
45. Roig F.J., Gonzalez-Candelas F., Amaro C. Domain organization and evolution of multifunctional autoprocessing repeats-in-toxin (MARTX) toxin in Vibrio vulnificus. Applied and Environmental Microbiology 2011, 77:657-668.
46. Satchell K.J. MARTX, multifunctional autoprocessing repeats-in-toxin toxins. Infection and Immunity 2007, 75:5079-5084.
47. Shen A. Autoproteolytic activation of bacterial toxins. Toxins 2010, 2:963-977.
48. Egerer M., Satchell K.J. Inositol hexakisphosphate-induced autoprocessing of large bacterial protein toxins. PLoS Pathogens 2010, 6:e1000942.